日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanotheranostic

利用靶向CCR2的细胞毒性纳米诊疗剂对胰腺癌肿瘤相关巨噬细胞进行治疗性重编程

Somani, Vikas Kumar; Zhang, Xiaohui; Chen, Timothy Hung-Po; Bulle, Ashenafi; Bansod, Sapana; Li, Lin; Geng, Yutong; Kang, Liang-I; Heo, Gyu Seong; Luehmann, Hannah; Zhang, Yuena; Saeed, Muhammad A; Lavine, Kory J; DeNardo, David G; Pachynski, Russell K; Liu, Yongjian; Lim, Kian-Huat

Phase 2 trial of pTVG-HP ± pTVG-AR DNA vaccines and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)

pTVG-HP ± pTVG-AR DNA 疫苗和帕博利珠单抗治疗转移性去势抵抗性前列腺癌 (mCRPC) 患者的 II 期试验

Kyriakopoulos, Christos E; Pachynski, Russell K; Eickhoff, Jens C; Tonelli, Tommaso P; Jeon, Donghwan; McNeel, Douglas G

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial

帕博利珠单抗联合多西他赛对比单药多西他赛治疗既往接受过治疗的转移性去势抵抗性前列腺癌:随机、双盲、III期KEYNOTE-921试验

Petrylak, Daniel P; Ratta, Raffaele; Matsubara, Nobuaki; Korbenfeld, Ernesto; Gafanov, Rustem; Mourey, Loic; Todenhöfer, Tilman; Gurney, Howard; Kramer, Gero; Bergman, Andries M; Zalewski, Pawel; De Santis, Maria; Armstrong, Andrew J; Gerritsen, Winald; Pachynski, Russell; Byun, Seok Soo; Retz, Margitta; Levesque, Eric; McDermott, Ray; Bracarda, Sergio; Manneh, Ray; Levartovsky, Meital; Li, Xin Tong; Schloss, Charles; Poehlein, Christian H; Fizazi, Karim

Synergistic potential of sipuleucel-T in enhancing immunotherapy for metastatic castration-resistant prostate cancer

sipuleucel-T 在增强转移性去势抵抗性前列腺癌免疫治疗中的协同潜力

Rawat, Kavita; Punia, Varnika; Mathews, Parker; McCoy, Sara; Song, Wilbur; Saeed, Muhammad A; Pachynski, Russell K

Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer

对血浆游离DNA进行基因组和表观基因组分析,揭示与致命性前列腺癌患者生存率降低相关的干细胞特征

Chauhan, Pradeep S; Alahi, Irfan; Sinha, Savar; Ledet, Elisa M; Mueller, Ryan; Linford, Jessica; Shiang, Alexander L; Webster, Jace; Greiner, Lilli; Yang, Breanna; Ni, Gabris; Dang, Ha X; Saha, Debanjan; Babbra, Ramandeep K; Feng, Wenjia; Harris, Peter K; Qaium, Faridi; Duose, Dzifa Y; Alexander, Sanchez E; Sherry, Alexander D; Jaeger, Ellen B; Miller, Patrick J; Caputo, Sydney A; Orme, Jacob J; Lucien, Fabrice; Park, Sean S; Tang, Chad; Pachynski, Russell K; Sartor, Oliver; Maher, Christopher A; Chaudhuri, Aadel A

A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer

一项评估阿特珠单抗联合或不联合人重组IL-7(CYT107)治疗晚期尿路上皮癌的II期开放标签、随机临床试验

Randy F Sweis ,Gurkamal S Chatta ,Rohit K Jain ,Helen Moon ,Scott Edward Delacroix ,Alana Fang ,Leonard D'Amico ,Angela Shaulov Kask ,Martin A Cheever ,Steven Fling ,Elad Sharon ,Andreanne Lacroix ,Judith C Kaiser ,Russell K Pachynski ,Evan Y Yu

IL-7: a potential next-generation adjuvant for immune cell therapies

IL-7:一种潜在的下一代免疫细胞疗法佐剂

Hotchkiss, Richard S; DiPersio, John F; Yee, Cassian; Pachynski, Russell K; Van Den Brink, Marcel R M

Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial

在 IMPACT II 期试验中评估免疫检查点阻断疗法对伴有 CDK12 有害改变的转移性去势抵抗性前列腺癌的疗效

Nguyen, Charles B; Reimers, Melissa A; Perera, Chamila; Abida, Wassim; Chou, Jonathan; Feng, Felix Y; Antonarakis, Emmanuel S; McKay, Rana R; Pachynski, Russell K; Zhang, Jingsong; Reichert, Zachery R; Palmbos, Phillip L; Caram, Megan E V; Vaishampayan, Ulka N; Heath, Elisabeth I; Hopkins, Alexander C; Cieslik, Marcin P; Wu, Yi-Mi; Robinson, Dan R; Baladandayuthapani, Veerabhadran; Chinnaiyan, Arul M; Alva, Ajjai S

Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide

转移性激素敏感性前列腺癌患者治疗后3个月和7个月的前列腺特异性抗原水平作为总生存期的预后标志物:来自SWOG S1216研究的结果,这是一项比较雄激素剥夺疗法联合奥特罗内或比卡鲁胺的3期随机试验。

Parikh, Mamta; Tangen, Catherine; Hussain, Maha H A; Gupta, Shilpa; Callis, Sam; Jo, Yeonjung; Harzstark, Andrea; Paller, Channing J; George, Saby; Zibelman, Matthew R; Cheng, Heather H; Maughan, Benjamin L; Zhang, Jingsong; Pachynski, Russell K; Bryce, Alan H; Lin, Daniel W; Quinn, David I; Lerner, Seth P; Thompson, Ian M; Dorff, Tanya B; Lara, Primo N; Agarwal, Neeraj

Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial

纳武利尤单抗联合瑞拉利单抗和纳武利尤单抗联合伊匹木单抗治疗晚期肾细胞癌患者:来自开放标签、随机、II期FRACTION-RCC试验的结果

Choueiri, T K; Kuzel, T M; Tykodi, S S; Verzoni, E; Kluger, H; Nair, S; Perets, R; George, S; Gurney, H; Pachynski, R K; Folefac, E; Castonguay, V; Lee, C-H; Vaishampayan, U; Miller, W H Jr; Bhagavatheeswaran, P; Wang, Y; Gupta, S; DeSilva, H; Lee, C-W; Escudier, B; Motzer, R J